Ocular Therapeutix (OCUL) Gross Margin (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Gross Margin of 85.08% for Q2 2026, down 48.0% year-over-year from 163.61% in Q2 2025, and down 2.97% on a QoQ basis from 87.68% in Q1 2026.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Gross Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Gross Margin for 13 years, with the latest figure at 85.08% in Q2 2026.
- Gross Margin for Q2 2026 came in at 85.08%, down 48.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 87.11% (down 230.0% YoY), and the FY2025 annual result was 87.35%, down 383.0% from the prior year.
- Gross Margin fell to 85.08% in Q2 2026, from 87.68% in the prior quarter.
- Over five years, Gross Margin peaked at 92.81% in Q4 2022 and troughed at 85.08% in Q2 2026.
- A 5-year average of 89.73% and a median of 90.61% in 2022 frame the typical range for Gross Margin.
- The widest annual swing landed in 2022, when Gross Margin jumped 229 bps; it then tumbled 527 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 92.81% in 2022, then decreased by 2 bps to 90.64% in 2023, then grew by 2 bps to 92.8% in 2024, then decreased by 5 bps to 87.97% in 2025, then slipped by 3 bps to 85.08% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 85.08% in Q2 2026, 87.68% in Q1 2026, and 87.97% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 84.20% |
| 10 | Ocular Therapeutix | 2.42 Bn | 2.42 Bn | 11.46 Mn | 85.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.08% |
| Mar 31, 2026 | 87.68% |
| Dec 31, 2025 | 87.97% |
| Sep 30, 2025 | 87.80% |
| Jun 30, 2025 | 85.56% |
| Mar 31, 2025 | 88.20% |
| Dec 31, 2024 | 92.80% |
| Sep 30, 2024 | 89.88% |
| Jun 30, 2024 | 90.82% |
| Mar 31, 2024 | 91.02% |
| Dec 31, 2023 | 90.64% |
| Sep 30, 2023 | 90.87% |
| Jun 30, 2023 | 91.41% |
| Mar 31, 2023 | 90.92% |
| Dec 31, 2022 | 92.81% |
| Sep 30, 2022 | 91.03% |
| Jun 30, 2022 | 90.58% |
| Mar 31, 2022 | 90.14% |
| Dec 31, 2021 | 91.00% |
| Sep 30, 2021 | 89.22% |